Switching factor products: selecting patients and managing the process

1. Hay CRM. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19R5S:660Q7.10.1111/hae.12169Search in Google Scholar

2. Sharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasmaQderived to recombinant factor VIII. Haemophilia 2001; 7: 766.Search in Google Scholar

3. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following widespread introduction of recombinant factor VIII replacement therapy. Transfusion Science 1998; 19R2S: 139T148.10.1016/S0955-3886(98)00024-1Open DOISearch in Google Scholar

4. Rubinger M, Lillicrap D, Rivard GE, et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian hemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14R2S: 281T286.10.1111/j.1365-2516.2007.01634.x18194308Open DOISearch in Google Scholar

5. Collins P, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: R4th editionS. UK Haemophilia Centre Doctors Organisation. Haematol 2013; 160: 153T170.10.1111/bjh.1209123157203Search in Google Scholar

6. Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367Q6370.10.1182/blood-2010-09-30866821471523Search in Google Scholar

7. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453T459.10.1056/NEJM1993021832807018421474Search in Google Scholar

8. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. ReFacto Phase 3 Study Group. The safety and efficacy of BQdomain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38T49.10.1046/j.1365-2516.2003.00708.x12558777Open DOISearch in Google Scholar

9. Rothschild C, Laurian Y, Satre EP et al. French previously untreated patients with severe haemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thrombosis and Haemostasis 1998; 80: 779 T783.10.1055/s-0037-1615358Search in Google Scholar

10. Gouw SC, van den Berg HM, le Cessie S et al. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis 2007; 5: 1383Q1390.10.1111/j.1538-7836.2007.02595.x17456190Search in Google Scholar

11. Franchini M, Makris M, Santagostino E, et al. NonQthromboticQ, nonQinhibitorQ associated adverse reaction to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand’s disease: a systematic review of prospective studies. Haemophilia 2012; 18R3S: e164T72.10.1111/j.1365-2516.2011.02745.x22250981Open DOISearch in Google Scholar

12. Gouw SC, van der Bom JG, Ljung R et al for the PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe haemophilia A. N Engl J Med 2013; 368: 231T9.10.1056/NEJMoa120802423323899Search in Google Scholar